FOURIER Cardiovascular Outcomes Trial1,4:
Repatha® + statin (key secondary endpoint)

Demonstrated significant risk reduction in time to MI, stroke, or CV death, whichever occurred first vs. placebo + statin

Time to CV death was not statistically significant vs. placebo (p=0.6188)

Demonstrated 20% RRR in time to CV death, heart attack, or stroke HR 0.80 (95% CI: 0.73, 0.88; p < 0.0001; patients with event: Repatha® 5.92%, placebo 7.35%)

Graphic depiction of cumulative incidence estimates for key secondary endpoint over 3

Primary composite endpoint

Demonstrated 15% reduced risk in time to CV death, heart attack, stroke, hospitalization for unstable angina or coronary revascularization, whichever occurred first vs. placebo ( HR 0.85, 95% CI: 0.79, 0.92; p < 0.0001; patients with event: Repatha® 9.75%, placebo 11.34%).

Study Design Patient characteristics Publication download

FOURIER cardiovascular outcomes study design1,4,7

FOURIER study was designed to evaluate CV risk reduction with Repatha® + statin in high-risk patients with CVD

The FOURIER study was conducted in a wide range of patients with established CVD, including those with MI, stroke, and PAD

FOURIER: A multicentre, double-blind, randomized, placebo-controlled study

Screening
  • Age ≥ 40 to ≤ 85 years
  • Prior MI, prior stroke, or symptomatic PAD
  • Additional risk factors (≥ 1 major or > 2 minor)*
  • Stable background lipid-lowering therapy (including effective dose of statin ± ezetimibe)
  • LDL-C ≥ 1.8 mmol/L [70 mg/dL] or non-HDL-C ≥ 2.6 mmol/L [100 mg/dL]

MAX = 15 WEEKS

Graphic depiction of study

Median follow-up duration: 2.2 years (26 months)
Primary endpoint: Composite of time to first event of CV death, MI, stroke, hospitalization for unstable angina or coronary revascularization
Key secondary endpoint: Composite of time to first event of CV death, MI, or stroke

Publication download

* Patients were required to have at least one major CV risk factor, e.g., diabetes mellitus, current daily cigarette smoking, age ≥ 65 years or recent MI (within 6 months); or two or more minor risk factors, e.g., history of coronary revascularization, elevated non-HDL-C, metabolic syndrome.
CV=cardiovascular; CVD=cardiovascular disease; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction; PAD=peripheral artery disease; Q2W=every 2 weeks; Q2W=monthly.

FOURIER trial patient characteristics1,4

FOURIER included patients you often see in your waiting room—those at risk for another CV event

Parameter Patients (N = 27,564)
Baseline LDL-C, mmol/L
(median interquartile range) 		2.4 mmol/L
(2.1–2.8)
Baseline statin use High intensity
Moderate intensity 		69%
30%
Selected CV risk factors Hypertension
Type 2 diabetes mellitus
Current cigarette use 		80%
36%
28%
Previous CV event* MI
Nonhemorrhagic stroke
PAD 		81%
19%
13%
Ezetimibe use 5%
Other CV medications Antiplatelet agents
Beta-blocker
ACE inhibitor
ARB 		93%
76%
56%
23%
  • The FOURIER trial enrolled patients with a median baseline LDL-C of 2.4 mmol/L
  • ~70% of patients in the Repatha® arm were on high-intensity statins
Publication download

* Patients could have more than one type of previous CV event.
ACE=angiotensin converting enzyme; ARB=angiotensin II receptor blocker; CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction; PAD=peripheral artery disease.

LAPLACE-2 study: Powerful LDL-C reduction shown in patients with primary hyperlipidemia1,5

Overall study population included those with ASCVD

Repatha® Q2W + statin provided an additional 73% LDL-C reduction overall (vs. placebo + statin; p < 0.0001).*

Graphic depiction of reduction in LDL-C with Repatha

Prevention of Cardiovascular Events: Repatha® is indicated as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels.

Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia [HeFH] and ASCVD): Repatha® is indicated for the reduction of elevated low density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia and ASCVD): as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C; as an adjunct to diet, alone or in combination with non-statin lipid-lowering therapies, in patients for whom a statin is contraindicated.

Up to 95% of patients achieved LDL-C < 1.8 mmol/L with Repatha® (Q2W and QM doses).

Study Design Publication download

* Overall difference, mean % change from baseline to week 12 in LDL-C, mean difference from placebo with Repatha® 140 mg Q2W (95% CI: -77%, -70%; p < 0.0001).

LAPLACE-2 study design1,5

Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled trial (N=1,896) in patients with primary hyperlipidemia (including 526 who had ASCVD) on maximum dose statin therapy. Patients were initially randomized to an open-label specific statin regimen for a 4-week lipid-stabilization period followed by random assignment to Repatha® 140 mg Q2W, Repatha® 420 mg QM or placebo for 12 weeks as add-on to daily statin therapy. Baseline LDL-C 2.8 mmol/L, measured after the lipid stabilization period and before administration of first dose of Repatha®. Primary endpoint: Mean % change from baseline in LDL-C at week 12.

Publication download

RUTHERFORD-2 study: Powerful LDL-C reduction in high-risk patients with HeFH1,6

Graphic depiction of reduction in LDL-C with Repatha

Background therapy: statin ± other lipid-lowering therapy, at 12 weeks.

Repatha® provided 61% additional reduction in mean LDL-C vs. patients on background therapy alone.

Study Design Publication download HeFH Criteria

RUTHERFORD-2 study design1,6

Phase 3, 12-week, randomized, double-blind, placebo-controlled trial in patients with HeFH (diagnosed by the Simon Broome criteria) (N=329). Patients randomized to Repatha® 140 mg Q2W, Repatha ® 420 mg QM or placebo for 12 weeks. All patients were on a stable dose of statin, with or without other lipid-lowering therapies, and 76% were on high-intensity statin therapy. Average LDL-C at baseline 4.0 mmol/L.

Primary endpoint: Mean % change from baseline in LDL-C at week 12. Secondary endpoints included proportion of patients achieving LDL-C < 1.8 mmol/L.

Publication download

HeFH criteria: Canadian Cardiovascular Society 2014 Position Statement on Familial Hypercholesterolemia

A genetic condition that causes high levels of LDL-C and can be diagnosed using the Simon Broome or Dutch Lipid Clinic diagnostic criteria.8 HeFH is now understood to affect about 1 in 250 people in Canada and globally.9

Simon Broome HeFH criteria8

Definite FH diagnosis

1. A plasma measurement of either:
Total cholesterol > 7.5 mmol/L (adult patient) or > 6.7 mmol/L (child aged < 16 years) LDL-C > 4.9 mmol/L (adult patient) or > 4.0 mmol/L (child aged < 16 years)

PLUS

2. Tendon xanthomas in the patient or any of the patient’s 1st- or 2nd-degree relatives

OR

3. DNA-based evidence in the patient of an LDL receptor mutation or other FH-related gene mutation

Probable FH diagnosis

1. A plasma measurement of either:
Total cholesterol > 7.5 mmol/L (adult patient) or > 6.7 mmol/L (child aged < 16 years) LDL-C > 4.9 mmol/L (adult patient) or > 4.0 mmol/L (child aged < 16 years)

PLUS

2. Family history of myocardial infarction before the age of:

  • 50 years in any 2nd-degree relative
  • 60 years in a 1st-degree relative

OR

3. Family history of total cholesterol > 7.5 mmol/L in any 1st- or 2nd-degree relative

Dutch Lipid Clinic HeFH criteria8

Points Criteria Diagnosis
1. First-degree relative with premature cardiovascular disease
OR
LDL-C > 95ᵗʰ percentile
OR
Personal history of premature peripheral or cerebrovascular disease,
OR
LDL-C 4.01–4.89 mmol/L 		Definite FH (≥ 8 points)
2. First-degree relative with tendon xanthoma or corneal arcus
OR
First-degree relative child ( < 18 years) with LDL-C > 95ᵗʰ percentile
OR
Personal history of coronary artery disease 		Probable FH (6–7 points)
3. LDL-C 4.91–6.44 mmol/L
4. Presence of corneal arcus in patient < 45 years
5. LDL-C 6.46–8.51 mmol/L Possible FH (3–5 points)
6. Presence of a tendon xanthoma
7. LDL-C > 8.53 mmol/L
OR
Functional mutation in the LDL-R gene

FH=familial hypercholesterolemia; HeFH=heterozygous familial hypercholesterolemia; LDL-C=low-density lipoprotein cholesterol.
Enrol your patients today

You are now leaving the Repatha.ca website

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to another Amgen Canada site?

Yes, leave Repatha.ca

You are now leaving the Repatha.ca website. Please note that these links are being provided as a convenience and for informational purposes only.

PROCEED